GEKA Stock Overview
Provides pharmaceutical and personal care products primarily in Latin America. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Genomma Lab Internacional, S.A.B. de C.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Mex$1.17 |
| 52 Week High | Mex$1.27 |
| 52 Week Low | Mex$0.66 |
| Beta | 0.48 |
| 11 Month Change | 0.86% |
| 3 Month Change | 40.96% |
| 1 Year Change | 58.11% |
| 33 Year Change | 61.38% |
| 5 Year Change | 33.71% |
| Change since IPO | 136.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| GEKA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.7% | 1.6% | 1.1% |
| 1Y | 58.1% | -19.0% | 7.2% |
Return vs Industry: GEKA exceeded the German Pharmaceuticals industry which returned -19% over the past year.
Return vs Market: GEKA exceeded the German Market which returned 7.2% over the past year.
Price Volatility
| GEKA volatility | |
|---|---|
| GEKA Average Weekly Movement | 6.7% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: GEKA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: GEKA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 1,614 | Juan Marco Sparvieri | www.genommalab.com |
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Latin America. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the relief of colitis, products to counter stress levels, anti-wrinkles, antacids, anti-ulcers, anti-flu, protection and sexual improvement, treatments against hemorrhoids, against varicose veins, osteoarthritis, ophthalmic medications, and infant nutrition. The company was incorporated in 1996 and is based in Mexico City, Mexico.
Genomma Lab Internacional, S.A.B. de C.V. Fundamentals Summary
| GEKA fundamental statistics | |
|---|---|
| Market cap | €1.14b |
| Earnings (TTM) | €74.32m |
| Revenue (TTM) | €809.98m |
15.5x
P/E Ratio1.4x
P/S RatioIs GEKA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GEKA income statement (TTM) | |
|---|---|
| Revenue | Mex$17.47b |
| Cost of Revenue | Mex$6.36b |
| Gross Profit | Mex$11.10b |
| Other Expenses | Mex$9.50b |
| Earnings | Mex$1.60b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.70 |
| Gross Margin | 63.56% |
| Net Profit Margin | 9.18% |
| Debt/Equity Ratio | 59.1% |
How did GEKA perform over the long term?
See historical performance and comparison